HK Stock Market Move | CRRC Corporation(01766) fell more than 7% after its performance announcement. Its annual net profit increased by more than 6% year-on-year, but the downturn in the urban rail industry may drag down its performance.
China CRRC (01766) fell more than 7% after the performance, as of the press release, down 6.67%, at 4.9 Hong Kong dollars, with a turnover of 86.41 million Hong Kong dollars.
CRRC Corporation (01766) fell more than 7% after the performance report, dropping by 6.67% to HK$4.9 at the time of publication, with a turnover of HK$86,413,100.
On the news front, CRRC Corporation released its annual performance report. In 2025, CRRC Corporation achieved operating income of RMB 273.063 billion, a year-on-year increase of 10.79%; and achieved a net profit attributable to the parent company of RMB 13.181 billion, a year-on-year increase of 6.40%. Looking at the fourth quarter alone, the main operating income was RMB 89.198 billion, a year-on-year decrease of 4.99%; and the net profit attributable to the parent company for the quarter was RMB 3.217 billion, a year-on-year decrease of 37.45%.
It is worth noting that in 2025, CRRC Corporation's railway equipment business income was RMB 123.608 billion, a year-on-year increase of 11.90%, mainly due to the growth in revenue from multiple units and locomotive business; while the revenue from urban rail and city infrastructure business was RMB 42.09 billion, a year-on-year decrease of 7.37%, mainly due to a decrease in revenue from urban rail vehicles. EB SECURITIES released a research report stating that considering the impact of the downturn in the urban rail industry on the company's performance, it reduced the net profit attributable to the parent company forecast for 2026-2027 by 3% each, to RMB 142.96 billion and RMB 153.87 billion, respectively.
Related Articles

HK Stock Market Move | Some concept stocks of innovative drugs have risen. In the first quarter, the total amount of innovative drugs in China exceeded 60 billion US dollars. The performance of pharmaceutical companies throughout the year is impressive.

From Clinical Trust to Standard Definition: Building a Dual Moat for Globalization and China's Sinking Market of ANGELALIGN (06699)

HK Stock Market Move | Spot gold back above $4500, Chifeng Jilong Gold Mining (06693) rises over 7%, LINGBAO GOLD (03330) rises over 6%.
HK Stock Market Move | Some concept stocks of innovative drugs have risen. In the first quarter, the total amount of innovative drugs in China exceeded 60 billion US dollars. The performance of pharmaceutical companies throughout the year is impressive.

From Clinical Trust to Standard Definition: Building a Dual Moat for Globalization and China's Sinking Market of ANGELALIGN (06699)

HK Stock Market Move | Spot gold back above $4500, Chifeng Jilong Gold Mining (06693) rises over 7%, LINGBAO GOLD (03330) rises over 6%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


